Compare USPH & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USPH | PGEN |
|---|---|---|
| Founded | 1990 | 1998 |
| Country | United States | United States |
| Employees | 5500 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1996 | 2013 |
| Metric | USPH | PGEN |
|---|---|---|
| Price | $72.40 | $3.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $101.67 | $8.33 |
| AVG Volume (30 Days) | 122.9K | ★ 4.1M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.42 | N/A |
| Revenue | ★ $780,990,000.00 | $230,981,000.00 |
| Revenue This Year | $10.62 | $1,115.92 |
| Revenue Next Year | $6.30 | $81.04 |
| P/E Ratio | $51.70 | ★ N/A |
| Revenue Growth | ★ 16.33 | N/A |
| 52 Week Low | $66.67 | $1.23 |
| 52 Week High | $93.50 | $5.47 |
| Indicator | USPH | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.22 | 51.39 |
| Support Level | $71.99 | $3.97 |
| Resistance Level | $76.84 | $4.40 |
| Average True Range (ATR) | 2.56 | 0.22 |
| MACD | -0.26 | -0.01 |
| Stochastic Oscillator | 7.12 | 30.70 |
US Physical Therapy Inc through its subsidiaries operate outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.